MA58049B1 - Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations - Google Patents

Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations

Info

Publication number
MA58049B1
MA58049B1 MA58049A MA58049A MA58049B1 MA 58049 B1 MA58049 B1 MA 58049B1 MA 58049 A MA58049 A MA 58049A MA 58049 A MA58049 A MA 58049A MA 58049 B1 MA58049 B1 MA 58049B1
Authority
MA
Morocco
Prior art keywords
mc2r
receptor
gem
antagonists
double
Prior art date
Application number
MA58049A
Other languages
English (en)
Inventor
Yunfei Zhu
Sangdon Han
Sun Hee Kim
Original Assignee
Crinetics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals, Inc. filed Critical Crinetics Pharmaceuticals, Inc.
Publication of MA58049B1 publication Critical patent/MA58049B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des composés qui sont des modulateurs du récepteur du sous-type 2 de la mélanocortine (MC2R), des procédés de préparation de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés, ainsi que des méthodes d'utilisation de tels composés dans le traitement d'affections, de maladies ou de troubles qui pourraient bénéficier de la modulation de l'activité de MC2R.
MA58049A 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations MA58049B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949854P 2019-12-18 2019-12-18
EP20903163.2A EP4077307B1 (fr) 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
PCT/US2020/064493 WO2021126693A1 (fr) 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations

Publications (1)

Publication Number Publication Date
MA58049B1 true MA58049B1 (fr) 2025-06-30

Family

ID=76477827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58049A MA58049B1 (fr) 2019-12-18 2020-12-11 Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations

Country Status (20)

Country Link
US (1) US12492181B2 (fr)
EP (2) EP4556067A3 (fr)
JP (2) JP7672406B2 (fr)
KR (2) KR20260100744A (fr)
CN (1) CN115335369B (fr)
AU (1) AU2020407016A1 (fr)
BR (1) BR112022012033A2 (fr)
CA (1) CA3164117A1 (fr)
DK (1) DK4077307T3 (fr)
ES (1) ES3031394T3 (fr)
FI (1) FI4077307T3 (fr)
HU (1) HUE071813T2 (fr)
IL (2) IL293941B2 (fr)
MA (1) MA58049B1 (fr)
MD (1) MD4077307T2 (fr)
MX (1) MX2022007439A (fr)
PL (1) PL4077307T3 (fr)
PT (1) PT4077307T (fr)
SI (1) SI4077307T1 (fr)
WO (1) WO2021126693A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
WO2021091788A1 (fr) 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) et leurs utilisations
JP7672406B2 (ja) 2019-12-18 2025-05-07 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
WO2023219952A1 (fr) * 2022-05-10 2023-11-16 Radionetics Oncology, Inc. Agents thérapeutiques ciblés sur le récepteur de type 2 de la mélanocortine (mc2r) et leurs utilisations
GB202302618D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
GB202302629D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
AU2024225939A1 (en) 2023-02-23 2025-08-21 Omass Therapeutics Limited Mc2r modulator compounds
WO2026047334A1 (fr) 2024-08-28 2026-03-05 Omass Therapeutics Limited Composés modulateurs de mc2r
WO2026047337A1 (fr) 2024-08-28 2026-03-05 Omass Therapeutics Limited Composés modulateurs de mc2r
GB202412595D0 (en) 2024-08-28 2024-10-09 Omass Therapeutics Ltd Mc2r modulator compounds

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
JP2881750B2 (ja) 1988-09-06 1999-04-12 エフ・ホフマン‐ラ ロシユ アーゲー ２‐（２‐フルオロフエニル）‐ピリジン
ATE372328T1 (de) 1997-06-24 2007-09-15 Janssen Pharmaceutica Nv Angiogenese-hemmende 5-substituierte-1,2,4- thiadiazolylderivate
US6833369B2 (en) 1997-06-24 2004-12-21 Janssen Pharmaceutica, Nv Angiogenesis inhibiting 5-substituted-1,2,4,-thiadiazolyl derivatives
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2000074679A1 (fr) 1999-06-04 2000-12-14 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
US7208503B2 (en) 2000-04-21 2007-04-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US20030158209A1 (en) 2001-10-09 2003-08-21 Neurocrine Biosciences Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US6664273B2 (en) 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
WO2003068738A1 (fr) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Derives de pyrrole utilises en tant que ligands de recepteurs de melanocortine
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ， インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
WO2004081643A1 (fr) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Reseau de lentilles a conversion de polarisation
EP1460073A1 (fr) 2003-03-20 2004-09-22 MyoContract Ltd. Dérivés substitués de la pipéridine et la pipérazine comme modulateurs du récepteur de la melanocortine-4
NZ544820A (en) 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
EP1663232B1 (fr) 2003-09-09 2007-10-03 F. Hoffmann-La Roche Ag Derives de 1-(2-amino-benzol)-piperazine en tant qu'inhibiteurs de l'absorption du glycocolle pour traiter des psychoses
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
KR20050045927A (ko) * 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
US7576076B2 (en) 2004-07-02 2009-08-18 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
EP1871762A2 (fr) 2005-04-18 2008-01-02 Neurogen Corporation Antagonistes cb1 heteroaryle substitue
CN101193635A (zh) * 2005-05-13 2008-06-04 莱西肯医药有限公司 多环化合物及其使用方法
CA2625877A1 (fr) 2005-10-18 2007-04-26 Merck & Co., Inc. Derives de spiropiperidine acyles utilises en tant que modulateurs vis-a-vis du recepteur de melanocortine-4
CA2634456A1 (fr) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulateurs de recepteurs muscariniques
JP2009534456A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2108641A1 (fr) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PT2344474E (pt) 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2715754B1 (fr) 2011-05-31 2015-07-29 Linak A/S Actionneur
JP2014237589A (ja) 2011-09-28 2014-12-18 日本曹達株式会社 環状アミン化合物および有害生物防除剤
WO2017046794A1 (fr) 2015-09-14 2017-03-23 The National Institute for Biotechnology in the Negev Ltd. Nouveaux dérivés de pipérazine et pipéridine, leur synthèse et utilisation associée pour inhiber l'oligomérisation de vdac, l'apoptose et le dysfonctionnement mitochondrial
US10434099B2 (en) 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
EP3199156A1 (fr) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Utilisation d'antagonistes du transporteur de la glycine 1 comme analgésiques du systeme nerveux central
EP3480198B1 (fr) 2016-06-30 2021-05-05 Riken Nouveau composé ou son sel pharmaceutiquement acceptable
US20210130291A1 (en) 2016-12-22 2021-05-06 The National Institute for Biotechnology in the Negev Ltd. Methods for treating diabetes using vdac1 inhibitors
US11377436B2 (en) 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
SG11202003407VA (en) 2017-10-17 2020-05-28 Merck Patent Gmbh PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
KR102695210B1 (ko) 2018-06-05 2024-08-13 크리네틱스 파마슈티칼스, 인크. 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도
WO2021091788A1 (fr) * 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) et leurs utilisations
JP7672406B2 (ja) 2019-12-18 2025-05-07 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Also Published As

Publication number Publication date
EP4556067A3 (fr) 2025-07-30
BR112022012033A2 (pt) 2022-10-11
EP4077307A1 (fr) 2022-10-26
CN115335369B (zh) 2024-07-02
ES3031394T3 (en) 2025-07-08
IL293941B1 (en) 2025-07-01
PT4077307T (pt) 2025-06-03
MD4077307T2 (ro) 2025-09-30
CA3164117A1 (fr) 2021-06-24
EP4077307A4 (fr) 2024-01-17
EP4556067A2 (fr) 2025-05-21
SI4077307T1 (sl) 2025-07-31
US12492181B2 (en) 2025-12-09
KR20260100744A (ko) 2026-06-30
IL293941A (en) 2022-08-01
JP2025124630A (ja) 2025-08-26
JP2023509310A (ja) 2023-03-08
MX2022007439A (es) 2022-07-19
CN115335369A (zh) 2022-11-11
JP7672406B2 (ja) 2025-05-07
AU2020407016A1 (en) 2022-07-07
DK4077307T3 (da) 2025-05-26
KR102978629B1 (ko) 2026-06-16
HUE071813T2 (hu) 2025-09-28
EP4077307B1 (fr) 2025-03-12
KR20220129553A (ko) 2022-09-23
WO2021126693A1 (fr) 2021-06-24
FI4077307T3 (fi) 2025-05-25
IL293941B2 (en) 2025-11-01
IL321386A (en) 2025-08-01
PL4077307T3 (pl) 2025-07-14
US20230135560A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
MA53665B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA51625B1 (fr) Procédé de production de modulateurs de somatostatine
EP4556067A3 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
EP4603142A3 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine à base de pipéridine spirocyclique (mc2r) et leurs utilisations
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA34474B1 (fr) Agonistes de gpr40
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA46018A (fr) Activateurs d'édition du génome
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MA44037A1 (fr) Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA38261A1 (fr) Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc)
MA37525B1 (fr) Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b